obesity
6 stories in The Vital Record · Condition
-
· Research
AstraZeneca's Oral GLP-1 Pill Trims 11.8% Body Weight in Phase 2 — Phase 3 Now Enrolling -
· Opinion
Sparing the muscle is not yet saving the strength -
· Research
A muscle-sparing antibody blunted lean-mass loss during tirzepatide weight loss in a phase 2 trial -
· Research
In a phase 3 trial, the GLP-1 pill orforglipron cut HbA1c about 1.1 points beyond placebo when added to titrated basal insulin -
· Research
Oral GLP-1 pill aleniglipron reaches up to 11.3% placebo-adjusted weight loss in a phase 2b trial -
· Clinical Trials
Lilly's retatrutide finishes Phase 3 obesity trial TRIUMPH-1 — but the data stay sealed